Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock Price

BDTXStock

$2.24−26.20%52W

Market Cap$128.36M

P/E5.23x

PEG Ratio—

Div yield—

Beta3.26

BDTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-15.89%

Price vs S&P 500 (4W)19.39%

VGM Score61.55

P/E Ratio (Annual)5.23x

P/CF (Annual)3.95x

Book Value / Share (Quarterly)$1.82

P/TBV (Annual)1.01x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.59

Price vs S&P 500 (YTD)-23.28%

EPS (TTM)$-0.76

10-Day Avg Trading Volume0.61M

EPS Excl Extra (TTM)$-0.76

EPS (Annual)$0.39

ROI (Annual)19.93%

Cash / Share (Quarterly)$2.06

P/E Basic Excl Extra (TTM)7.66x

P/E Normalized (Annual)5.23x

ROA (Last FY)15.64%

EBITD / Share (TTM)$-0.93

ROE (5Y Avg)-55.45%

Cash Flow / Share (Annual)$0.52

P/B Ratio1.12x

P/B Ratio (Quarterly)1.17x

Net Income / Employee (Annual)$1,065,100

Net Interest Coverage (TTM)-413.41x

ROA (TTM)-28.80%

EV / EBITDA (TTM)6.76x

EPS Incl Extra (Annual)$0.39

Current Ratio (Annual)8.42x

Quick Ratio (Quarterly)8.14x

3-Month Avg Trading Volume1.41M

52-Week Price Return-26.20%

EV / Free Cash Flow (Annual)2.93x

P/E Incl Extra (TTM)7.66x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.60

P/S Ratio (Annual)1.67x

Asset Turnover (Annual)0.49x

52-Week High$4.94

EPS Excl Extra (Annual)$0.39

Tangible BV CAGR (5Y)82.07%

26-Week Price Return-4.65%

Quick Ratio (Annual)8.18x

13-Week Price Return-39.30%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.46x

Enterprise Value$86.85M

Book Value / Share Growth (5Y)-25.45%

Revenue / Employee (Annual)$3,333,300

Pretax Margin (Annual)31.95%

Cash / Share (Annual)$2.25

3-Month Return Std Dev94.19%

Net Income / Employee (TTM)$-2,057,700

ROE (Last FY)19.93%

Net Interest Coverage (Annual)-12.43x

EPS Basic Excl Extra (Annual)$0.39

EV / Free Cash Flow (TTM)5.08x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.76

ROI (TTM)-36.37%

Revenue / Share (Annual)$1.22

Tangible BV / Share (Annual)$3.18

Forward P/E4.75x

Price vs S&P 500 (52W)-44.51%

P/E Ratio (TTM)7.66x

Year-to-Date Return-11.32%

5-Day Price Return4.61%

EPS Normalized (Annual)$0.39

ROA (5Y Avg)-40.44%

Net Profit Margin (Annual)31.95%

Month-to-Date Return27.51%

Cash Flow / Share (TTM)$-2.09

EBITD / Share (Annual)$0.22

Operating Margin (Annual)17.89%

P/CF (TTM)5.78x

ROI (5Y Avg)-55.45%

P/E Excl Extra (TTM)7.66x

EPS Basic Excl Extra (TTM)$-0.76

P/TBV (Quarterly)0.87x

P/B Ratio (Annual)1.23x

Book Value / Share (Annual)$1.96

Price vs S&P 500 (13W)-42.09%

Beta3.26x

P/FCF (Annual)3.95x

Revenue / Share (TTM)$0.00

ROE (TTM)-36.37%

52-Week Low$1.60

vGradeA

mGradeC

vgmGradeB

BDTX Earnings Surprise History

Q2 25-0.19est. -0.23

Q3 25-0.15est. -0.23

Q4 25-0.14est. -0.17

Q1 26-0.16est. -0.21

Q2 26-0.17est. -0.20

BDTX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.20

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
BDTXBlack Diamond Therapeutics, Inc. Common Stock	A	—	C	$2.24
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Black Diamond Therapeutics, Inc. Common Stock

Black Diamond Therapeutics is a clinical-stage oncology company developing small molecule therapies targeting specific cancer mutations across multiple tumor types. The company's proprietary Mutation-Allostery-Pharmacology platform identifies drug targets in families of oncogenic mutations, addressing a significant market opportunity in precision cancer medicine. Its pipeline includes two lead programs, BDTX-4933 and BDTX-1535.